Noble Life Sciences

Noble Life Sciences is a preclinical contract research organization (CRO) that specializes in providing comprehensive support for drug and device development, focusing on oncology, infectious diseases, and diabetes. Founded in 2010 by Alain Cappeluti and Kenneth Carter, Noble Life Sciences is headquartered in Gaithersburg, US. It has engaged in 5 deals, with its most recent funding event occurring on January 15, 2014, where it raised USD 0. 1 million during its Seed round from the Maryland Technology Development Corporation.

The company has primarily focused on preclinical research services without significant pivots in strategy. Noble Life Sciences operates as a full-service preclinical contract research organization (CRO), specializing in comprehensive solutions for drug and device development across various therapeutic areas, including oncology, infectious diseases, and diabetes. Core offerings encompass contract research and development, analytical testing, bioanalysis, pharmacodynamic modeling, and preclinical safety testing. The company serves a diverse clientele ranging from biotech firms to pharmaceutical companies, providing essential research services aimed at accelerating the transition from discovery to commercialization.

Noble's preclinical services are utilized primarily in North America and Europe, facilitating advancements in cell and gene therapies, as well as innovative medical devices. By delivering high-quality, customized preclinical services, Noble addresses complex research challenges, thereby supporting clients in achieving regulatory compliance and expediting their product pipelines. Noble Life Sciences generates revenue through a B2B model, primarily engaging with pharmaceutical and biotechnology companies that require preclinical research services. Transactions typically involve contract agreements for specific research projects, with clients paying for services rendered based on established pricing structures that reflect the complexity and scope of the work.

Flagship services, such as bioanalytical assays and pharmacodynamic models, are critical to the company’s revenue stream, and clients may engage Noble on a project basis or through longer-term research partnerships. These agreements are often structured to include milestone payments linked to the progression of studies, ensuring consistent financial inflow as projects advance. The company’s adherence to GLP (Good Laboratory Practice) standards enhances its appeal to clients seeking reliable and compliant research outcomes. In January 2014, Noble Life Sciences raised USD 0.

1 million in Seed funding, which will be utilized to enhance its research capabilities and expand service offerings. The company plans to introduce new bioanalytical products designed to meet emerging market needs by the end of 2024. Additionally, Noble aims to expand its operations into Europe and Asia, targeting these regions for new market opportunities within the next two years.